HIV-infected individuals are living longer in the antiretroviral therapy (ART) era, but remain at high risk for non-AIDS-associated diseases typically associated with aging and continue to have a markedly shorter life expectancy than the general population. The mechanisms mediating this increased risk of death remain unknown. While soluble inflammatory markers predict earlier mortality in this setting, no study has assessed whether T cell senescence predicts death among HIV-infected individuals maintaining treatment-mediated viral suppression. The goal of this proposal is to assess the relative contributions of persistent inflammation and immune senescence in early mortality in this setting. To address these issues, we propose a nested case control study within the Study of the Ocular Complications of AIDS (SOCA), a cohort of over 2,200 HIV-infected individuals who initiated antiretroviral therapy with a diagnosis of AIDS (CD4 count<200 or an opportunistic disease) and have been followed for nearly 12,000 person-years. Over 1000 participants are maintaining plasma HIV RNA levels <400 copies/ml on ART and 92 of these participants subsequently died from non-traumatic causes with a most recent plasma HIV RNA level <400 copies/ml. We will sample cryopreserved peripheral blood mononuclear cells (PBMC) and plasma from the last timepoint prior to death in these in these participants and match each case to 2 controls by duration of viral suppression, age, gender, and nadir CD4 count. We will compare soluble markers of inflammation and microbial translocation as well as levels of T cell activation, senescence, and proliferative capacity between cases and controls. We will also measure CMV-specific CD8 responses as asymptomatic CMV co-infection has been associated with T cell senescence and mortality in elderly HIV-uninfected individuals. We hypothesize that higher CMV-specific CD8 responses will be associated with greater T cell senescence, which will predict earlier mortality independent of plasma inflammatory markers. This study will be the first to assess whether T cell senescence predicts earlier mortality in HIV-infected individuals maintaining treatment-mediated viral suppression, potentially identifying targets for future interventions.

Public Health Relevance

HIV-infected individuals are living longer in the antiretroviral therapy (ART) era, but remain at high risk for non-AIDS-associated diseases typically associated with aging and continue to have a markedly shorter life expectancy than the general population. The mechanisms mediating this increased risk of death remain unknown. While soluble inflammatory markers predict earlier mortality in this setting, no study has assessed whether T cell senescence predicts death among HIV-infected individuals maintaining treatment-mediated viral suppression. The goal of this proposal is to assess the relative contributions of persistent inflammation and immune senescence in early mortality in this setting.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI087035-02
Application #
8071542
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Livnat, Daniella
Project Start
2010-05-15
Project End
2012-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
2
Fiscal Year
2011
Total Cost
$192,049
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Tenorio, Allan R; Zheng, Yu; Bosch, Ronald J et al. (2014) Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 210:1248-59
Hunt, Peter W; Sinclair, Elizabeth; Rodriguez, Benigno et al. (2014) Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 210:1228-38
Lee, Sulggi A; Sinclair, Elizabeth; Jain, Vivek et al. (2014) Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis 210:374-82
Lee, Sulggi A; Sinclair, Elizabeth; Hatano, Hiroyu et al. (2014) Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One 9:e89444
Serrano-Villar, Sergio; Sainz, Talia; Lee, Sulggi A et al. (2014) HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 10:e1004078
Hunt, Peter W; Shulman, Nancy S; Hayes, Timothy L et al. (2013) The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood 121:4635-46
Lok, Judith J; Hunt, Peter W; Collier, Ann C et al. (2013) The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. AIDS 27:2101-10
Hsue, Priscilla Y; Deeks, Steven G; Hunt, Peter W (2012) Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 205 Suppl 3:S375-82
Sacre, Karim; Hunt, Peter W; Hsue, Priscilla Y et al. (2012) A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS 26:805-14